<p>The Q4 earnings report for <strong>IDEXX Laboratories</strong> (NASDAQ:IDXX) was released on Monday, February 2, 2026 at 06:30 AM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>IDEXX Laboratories beat estimated earnings by 5.0%, reporting an EPS of $3.08 versus an estimate of $2.93.</p>
<p>Revenue was up $136.71 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>The company beat on EPS by $0.08 in the previous quarter, leading to a 0.0% increase share price change the next day.</p>
<p>Here's a look at IDEXX Laboratories's past performance:</p>
<p></p><table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2025</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>3.14</td>
<td>3.3</td>
<td>2.85</td>
<td>2.40</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>3.22</td>
<td>3.5</td>
<td>2.91</td>
<td>2.53</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.07B</td>
<td>1.07B</td>
<td>998.15M</td>
<td>936.68M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.10B</td>
<td>1.11B</td>
<td>998.43M</td>
<td>954.29M</td>
</tr>
</tbody>
</table><p></p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>IDEXX Laboratories management provided guidance for FY 2026, expecting earnings between $14.29 and $14.8 per share.</p>
<p>To track all earnings releases for IDEXX Laboratories visit their earnings calendar here. </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>

IDNA

<p>IDEXX Laboratories (NASDAQ:IDXX) reported Q4 earnings on February 2, 2026, beating estimates with an EPS of $3.08, surpassing the $2.93 forecast by 5%. Revenue increased by $136.71 million year-over-year. The company also provided FY 2026 guidance, expecting earnings between $14.29 and $14.8 per share. Past performance shows a consistent trend of beating EPS estimates, although stock price changes can be influenced by guidance rather than just earnings results.</p>

benzinga_article

Health Care Select Sector SPDR

iShares Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

VanEck Biotech ETF

SPDR S&P Health Equip

iShares US Healthcare Providers

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

IDEXX Labs

First Trust NYSE Arca Biotech Index Fd

iShares US Medical Devices

SPDR S&P Biotech

IDEXX Laboratories: Q4 Earnings Insights